Iaroslav Gennadevich MURAZOV
(Rusya)
Anna Sergeevna ARTEMYEVA
(Rusya)
Anna Olegovna NIUGANEN
(Rusya)
Konstantin Yurjevich SENCHIK
(Rusya)
Yıl: 2021Cilt: 4Sayı: 3ISSN: 2618-6454 / 2618-6454Sayfa Aralığı: 164 - 174İngilizce

17 0
Isolated effects of regional hyperthermic perfusion on the development of peritoneal metastasis and overall survival in rats with transplanted high-grade ovarian carcinoma
Aim: To construct a perfusion circuit for experimental open hyperthermic intraperitoneal perfusion (HIPEP) and to evaluate the antitumor effects of regional hyperthermia in a model of advanced syngeneic high-grade ovarian carcinoma in vivo. Method: 24 mature female Wistar rats underwent intraperitoneal transplantation of ascitic ovarian tumor 1×107 cells per rat. 48 hours after transplantation the animals were randomized into two groups: I. NIPEP group (12 rats) – normothermic intraperitoneal perfusion (NIPEP) with normal saline at room temperature during 45 minutes; II. HIPEP group (12 rats) – open hyperthermic intraperitoneal perfusion (HIPEP) with normal saline (40.5-41.5 °C) during 45 minutes. Endpoints included overall survival (OS), the total peritoneal cancer index (PCI), ascites weight and the grade of ascites hemorrhage. Results: In both groups all animals survived the procedure, in the HIPEP group one rat died due to infectious complications on day 32. Compared with NIPEP group HIPEP with normal saline significantly increased the median OS from 19 to 39 days (log-rank test, P=0.0013), reducing the risk of death by 68% (HR=0.32; 95% CI 0.13-0.82). The open HIPEP without a cytostatic was associated with significantly lower total PCI (14 vs 5 points, P=0.0155). In the HIPEP group 3 of 12 animals had intrathoracic tumor spread with malignant pleural effusion without signs of peritoneal carcinomatosis and ascites. Conclusion: The transplanted syngeneic tumor is a valid model that allows to quantitatively assess antitumor activity of intraperitoneal perfusion therapy. Our preclinical data confirmed the role of regional hyperthermia in the treatment of peritoneal carcinomatosis in ovarian tumors.
DergiAraştırma MakalesiErişime Açık
  • [1]Helderman RFCPA, Löke DR, Kok HP et al. Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers (Basel). 2019; 11(1): 78.
  • [2]Reid B.M., Permuth J.B., Sellers T.A. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1): 9–32.
  • [3]Goodman MD, McPartland S, Detelich D et al. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016; 7(1): 45-57.
  • [4]Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990; 50(18): 5790-94.
  • [5]Hager E.D. Intracavitary Hyperthermic Perfusion. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience 2000-2013, https://www.ncbi.nlm.nih.gov/books/NBK6 059.
  • [6]Cortez AJ., Tudrej P, Kujawa KA et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018; 81(1): 17-38.
  • [7]Jewell A, McMahon M, Khabele D. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. Cancers (Basel). 2018; 10(9): 296.
  • [8]Murazov Ia.G., Niuganen A.O., Artemyeva A.S. Experimental modeling of ovarian carcinoma. Laboratory Animals for Science. 2020; 3. https://doi.org/10.29296/2618723X-2020- 03-05 (In Russian).
  • [9]Pelz JO, Doerfer J, Hohenberger W et al. A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer. 2005; 5:56.
  • [10]Badrudin D, Sideris L, Perrault-Mercier C, et al. Comparison of open and closed abdomen techniques for the delivery of intraperitoneal pemetrexed using a murine model. J Surg Oncol. 2018; 117(6): 1318-22.
  • [11]Park EJ, Ahn J, Gwak SW, et al. Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model. Ann Surg Oncol. 2018; 25(11): 3185-92.
  • [12]McCabe-Lankford E, Peterson M, McCarthy B. et al. Murine Models of Intraperitoneal Perfusion for Disseminated Colorectal Cancer. J Surg Res. 2019;233:310-22.
  • [13]Pogosyants EE, Prigozhina EL, Egolina NA. Transplantable rat ovary ascitic tumor. Vopr Oncol 8: 29-36, 1962 (In Russian).
  • [14]Klaver YL, Hendriks T, Lomme RM, et al. Intraoperative hyperthermic IP CT after CRS cytoreductive surgery for peritoneal carcinomatosis in an experimental model. Br J Surg. 2010; 97(12): 1874-80.
  • [15]Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982;38(1): 163-70.
  • [16]Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003; 12(3):689–701.
  • [17]Vergote I, Harter P, Chiva L. Is There a Role for Intraperitoneal Chemotherapy, Including HIPEC, in the Management of Ovarian Cancer? J Clin Oncol. 2019; 37(27): 2420- 23.
  • [18]Gremonprez F, Willaert W, Ceelen W. Intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis: review of animal models. J Surg Oncol. 2014; 109(2): 110-16.
  • [19]González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010; 2(2):68-75.
  • [20]Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003; 12(3): 689–701.
  • [21]Harris SJ., Brown J, Lopez J et al. Immunooncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016; 13(2): 171-93.
  • [22]Skitzki JJ., Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. 2009; 10(6): 550-58.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.